Ocugen (NASDAQ:OCGN) PT Raised to $5.00 at Chardan Capital

Ocugen (NASDAQ:OCGN) had its price target increased by Chardan Capital from $4.00 to $5.00 in a research report report published on Monday morning, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, HC Wainwright restated a buy rating and set a $7.00 target price on shares of Ocugen in a report on Wednesday, April 3rd.

Ocugen Price Performance

Shares of NASDAQ OCGN opened at $1.18 on Monday. The firm has a market capitalization of $303.64 million, a PE ratio of -4.37 and a beta of 3.51. The company has a current ratio of 2.51, a quick ratio of 2.51 and a debt-to-equity ratio of 0.07. Ocugen has a 1 year low of $0.35 and a 1 year high of $2.11. The firm’s 50-day moving average is $1.28 and its 200-day moving average is $0.75.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings data on Tuesday, April 16th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $6.04 million for the quarter. Equities analysts expect that Ocugen will post -0.29 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ocugen stock. David J Yvars Group acquired a new stake in Ocugen, Inc. (NASDAQ:OCGN) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,170 shares of the company’s stock, valued at approximately $35,000. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.